AcelRx Pharmaceuticals GAAP EPS of -0.16 beats by 0.06
| TLPH Stock | 0.64 0.02 3.23% |
Under 72 percent of all Talphera's traders are curious in acquiring. The analysis of overall sentiment of trading Talphera stock suggests that a large number of investors are confidant at this time. Talphera's investing sentiment shows overall attitude of investors towards Talphera.
Talphera |
AcelRx Pharmaceuticals beats expectations with Q1 2024 financial results, reporting a GAAP EPS of -0.16, surpassing estimates by 0.06.
Read at seekingalpha.com
 |
Talphera Fundamental Analysis
We analyze Talphera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Talphera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Talphera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Talphera is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Talphera Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Talphera stock to make a market-neutral strategy. Peer analysis of Talphera could also be used in its relative valuation, which is a method of valuing Talphera by comparing valuation metrics with similar companies.
Peers
Talphera Related Equities
| TEVA | Teva Pharma | 3.66 | ||||
| EBS | Emergent Biosolutions | 0.50 | ||||
| NBIX | Neurocrine Biosciences | 0.34 | ||||
| HLN | Haleon Plc | 0.10 | ||||
| ALVO | Alvotech | 1.65 |
Complementary Tools for Talphera Stock analysis
When running Talphera's price analysis, check to measure Talphera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talphera is operating at the current time. Most of Talphera's value examination focuses on studying past and present price action to predict the probability of Talphera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talphera's price. Additionally, you may evaluate how the addition of Talphera to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |